Imagen de Portada

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohamed El‐Kassas, Hala Mostafa, Wessam Abdellatif, Sohier Shoman, Gamal Esmat, Mayur Brahmania, Hongqun Liu, Samuel S. Lee
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
por: Mohamed El‐Kassas, et al.
Publicado: (2025)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
por: Jiru Li, et al.
Publicado: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
por: Hassan Javed, et al.
Publicado: (2025)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
por: Gamal Shiha, et al.
Publicado: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
por: Veeral Ajmera, et al.
Publicado: (2026)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
por: Chia‐Chih Kuo, et al.
Publicado: (2025)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
por: Ankit Kumar, et al.
Publicado: (2026)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
por: Matheus Souza, et al.
Publicado: (2025)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
por: Mark C. C. Cheah, et al.
Publicado: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
por: Margaret L. P. Teng, et al.
Publicado: (2024)

Research Communication: Effects of Screening Colonoscopy on Colorectal Cancer Mortality: Lessons From Comparative Analyses of Randomised Trials
por: Hermann Brenner, et al.
Publicado: (2025)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
por: Gamal Shiha, et al.
Publicado: (2025)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
por: Maryam Zafer, et al.
Publicado: (2024)

Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial
por: Louise F. Risnes, et al.
Publicado: (2025)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
por: Hannah Mohr, et al.
Publicado: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
por: Suzanne Sharpton, et al.
Publicado: (2026)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
por: Mustafa Mohamedrashed, et al.
Publicado: (2024)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
por: Vincent L. Chen
Publicado: (2025)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
por: R. Sinha, et al.
Publicado: (2025)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
por: Wah‐Kheong Chan, et al.
Publicado: (2024)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial
por: Yu Yang, et al.
Publicado: (2024)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
por: Maral Amangurbanova, et al.
Publicado: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
por: Nobuharu Tamaki, et al.
Publicado: (2025)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
por: Federico Perna, et al.
Publicado: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
por: Takefumi Kimura
Publicado: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
por: Mary Yue Wang, et al.
Publicado: (2025)

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations
por: Niharika Samala, et al.
Publicado: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
por: Ziheng Calvin Xu, et al.
Publicado: (2025)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
por: Nauzer Forbes, et al.
Publicado: (2024)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
por: Eduardo Vilar‐Gomez, et al.
Publicado: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
por: Qiang Hu, et al.
Publicado: (2024)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
por: Darren Jun Hao Tan, et al.
Publicado: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
por: Xiaojuan Liu, et al.
Publicado: (2025)

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
por: Carlos José Pirola, et al.
Publicado: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)

Letter on ‘Clinical Trial: Effect of a 28‐Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis ( EndoFOD )—A Randomised, Controlled Crossover Feeding Study’
por: Wancheng Zhao, et al.
Publicado: (2025)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
por: Sofia Tsitsou, et al.
Publicado: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
por: Yewan Park, et al.
Publicado: (2024)

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
por: Daniela S. Allende, et al.
Publicado: (2024)